General Information of This Drug (ID: DM9NJ52)

Drug Name
Fosinopril   DM9NJ52
Synonyms
Acecor; Fosenopril; Monopril; Staril; FOSINOPRIL SODIUM; Fosinopril (INN); Fosinopril [INN:BAN]; Monopril (TN); SQ-28555; SQ-28,555; Fosinopril, (1(S*(R*)),2 alpha,4 beta)-Isomer; (2S,4S)-4-cyclohexyl-1-[2-[(2-methyl-1-propanoyloxypropoxy)-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid; (2S,4S)-4-cyclohexyl-1-[2-[[(1S)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid; (2S,4S)-4-cyclohexyl-1-{2-[(2-methyl-1-propionyloxy-propoxy)-(4-phenyl-butyl)-phosphinoyl]-acetyl}-pyrrolidine-2-carboxylic acid; (4S)-4-cyclohexyl-1-({[2-methyl-1-(propanoyloxy)propoxy](4-phenylbutyl)phosphoryl}acetyl)-L-proline; (4S)-4-cyclohexyl-1-{[{[2-methyl-1-(propanoyloxy)propyl]oxy}(4-phenylbutyl)phosphoryl]acetyl}-L-proline; 4-cyclohexyl-1-[2-[(2-methyl-1-propanoyloxypropoxy)-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid
Indication
Disease Entry ICD 11 Status REF
Chronic heart failure BD1Z Approved [1]
Hypertension BA00-BA04 Approved [2]
Malignant essential hypertension BA00 Approved [1]
Therapeutic Class
Antihypertensive Agents
Drug Type
Small molecular drug
Structure
3D MOL is unavailable 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

2 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Fosinopril + Diltiazem DCRFL2W Diltiazem Hypertension [3]
Pravastatin + Fosinopril DCEYFCZ Pravastatin Microalbuminuria [4]
------------------------------------------------------------------------------------

References

1 Fosinopril FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6456).
3 ClinicalTrials.gov (NCT04467931) ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
4 ClinicalTrials.gov (NCT03073018) Prevention of Renal and Vascular Endstage Disease Intervention Trial